Orca Bio

1.1 Identity, product, and operating footprint

Orca Bio is headquartered in Menlo Park, California, and develops precision cell therapies for blood cancers and autoimmune disease. The company’s lead product, TREGZI, was known during development as Orca-T and is manufactured from matched-donor cells as three defined components: hematopoietic stem and progenitor cells, highly purified regulatory T cells, and conventional T cells. The product is administered in the matched-donor transplant setting rather than as a standalone outpatient biologic. Independent reporting and company materials describe the platform as a high-precision approach intended to control graft composition and reduce chronic graft-versus-host disease while preserving graft-versus-leukemia activity. Orca Bio’s dedicated manufacturing footprint and the product’s patient-specific workflow make execution capacity and logistics central parts of the company identity, not merely back-office considerations. The assigned evidence supports a U.S.-focused commercial-stage company, but does not establish a verified current employee count, revenue base, customer count, or international filing program.[CO001, CO002, CO003, CO004]

1.2 Leadership, governance, and stakeholder dependence

Nate Fernhoff is identified in company announcements as co-founder and chief executive officer, placing a founder-led executive at the center of regulatory and commercial messaging. The Pharma Letter reports the May 2026 appointment of Bijan Nejadnik as chief medical officer, a relevant addition as the company transitions into commercial execution. An assigned company job posting also describes a Head of Business Development role reporting to the CFO or Head of Strategy and working across the C-suite, board, scientific, clinical, regulatory, manufacturing, and commercial teams; this is evidence of a needed capability, not proof that the role was filled. The public record in this pool does not provide a complete board roster, ownership table, liquidation preferences, or a fully enumerated executive bench. The resulting governance risk is concentrated execution dependence: manufacturing, regulatory compliance, clinical credibility, commercial center onboarding, and financing all need to scale together.[CO005, CO006, CO007, CO008]

1.3 Financing, approval, and unresolved scale questions

The assigned sources describe a $192 million Series D in November 2019 and a $250 million Series F in January 2026, with Lightspeed Venture Partners identified as a lead investor for the recorded rounds. The same third-party profile states $300 million of total funding despite listing those two larger round amounts, so total capital raised is unresolved rather than safely inferred by addition. These are financing figures, not cash-on-hand, revenue, or runway. The company also moved through FDA priority review, a three-month review extension tied to updated chemistry, manufacturing, and controls information, and U.S. approval of TREGZI on June 30, 2026. The approval is a material milestone, but it does not establish commercial demand or realized revenue. One independent article reports a $428,000 wholesale acquisition cost and an expectation of reaching approximately 25 U.S. transplant centers by year-end 2026; those are reported launch parameters, not observed sales. The key diligence questions are current cash and burn, actual center activation and orders, payer coverage, manufacturing throughput, post-approval safety monitoring, and the economics of future pipeline expansion.[CO009, CO010, CO011, CO012, CO016]

1.4 Exhibits

2.1 Market boundary and status quo

Tregzi addresses a specific slice of hematology care: adults with hematologic malignancies receiving a matched-donor hematopoietic stem-cell transplant with myeloablative conditioning. FDA and patient-facing coverage describe the intervention as a one-time donor-derived transplant component intended to improve chronic GVHD-free survival, not as a general blood-cancer drug or a treatment for every GVHD case. The status quo is conventional allogeneic transplantation with pharmacologic GVHD prophylaxis, while adjacent alternatives include other prophylaxis regimens and post-transplant treatment for established acute or chronic GVHD. This boundary excludes autologous CAR-T, unrelated solid-tumor cell therapy, and the broader spend on all immunosuppressants. The distinction matters because broad GVHD market estimates include prevention and treatment, acute and chronic disease, multiple modalities, and geographies that are not all eligible for Tregzi.[CM001, CM002, CM004]

2.2 Sizing lenses and what they do not prove

Two commercial research estimates put the 2026 global GVHD-treatment market at $3.32 billion and $3.2 billion, with forecasts to 2031 or 2036 and different CAGRs. Those estimates are useful as an outer market reference, not as Orca's SAM: one explicitly says its build starts with transplant activity, GVHD incidence, treatment eligibility, therapy mix, and net price, while also warning that published numbers differ when authors choose different patient pools, prevention inclusion, treatment lines, and pricing assumptions. The company-specific evidence is more constrained: the initial launch was described as a handful of centers with a plan for about 25 centers by year-end 2026, and the trial involved 19 leading centers. A defensible SOM therefore requires observed center activation, eligible patient flow, payer coverage, orders, and realized net price; none of those launch outcomes is yet disclosed in the assigned evidence.[CM005, CM006, CM007, CM008, CM009]

2.3 Buyer, payer, and adoption path

The economic buyer is likely the transplant hospital and its pharmacy or cellular therapy service, while the clinical user is the transplant physician and cell processing team; the ultimate payer can be commercial insurance or a government program. The treatment's $428,000 wholesale acquisition cost makes budget timing, benefit classification, prior authorization, and evidence of avoided GVHD costs central adoption questions. Operationally, the product requires matched-donor collection, controlled cell processing, and a reported 72-hour vein-to-vein objective, so center qualification and logistics are part of the product rather than a conventional drug-distribution afterthought. CMS's CGT Access Model shows that state Medicaid programs may use outcomes-based agreements, negotiated discounts, and standard access policies for expensive cell and gene therapies, but its initial focus is sickle-cell gene therapy and participation is voluntary; it is a reimbursement precedent, not proof of Tregzi coverage. CIBMTR's center reporting infrastructure can support market enumeration, but its public materials also identify convenience samples that are not generalizable.[CM010, CM011, CM012, CM013, CM014]

2.4 Growth drivers, constraints, and valuation relevance

The strongest demand driver is clinical: the randomized Precision-T evidence reported 78% one-year chronic GVHD-free survival for Tregzi versus 38% for conventional transplant, while the FDA and CURE summaries describe the same direction of benefit. A second driver is a large unmet-burden context: chronic GVHD can affect multiple organs and create long-term morbidity. The constraints are equally material. The indication is narrow, manufacturing is patient- and donor-dependent, the launch requires center onboarding, and the company has had to provide additional chemistry, manufacturing, and controls information during regulatory review. Published market reports also describe established drug modalities and incumbent companies in the broader GVHD market. For valuation, this supports a differentiated but execution-sensitive adoption case: clinical efficacy can justify attention, but realized penetration, reimbursement, capacity, and repeatable delivery remain the proof points that convert an outer market estimate into revenue.[CM015, CM016, CM018]

2.5 Exhibits

3.1 Landscape and buyer alternatives

The most immediate alternative to TREGZI is not another precision T-cell product but the existing matched-donor allogeneic hematopoietic cell transplant pathway using an unmanipulated donor allograft and conventional GVHD prophylaxis. The ClinicalTrials.gov record defines the randomized Phase 3 comparator as standard-of-care alloHCT with an unmanipulated graft and tacrolimus plus methotrexate, while the experimental arm uses Orca-T followed by single-agent tacrolimus. That makes the transplant center and physician the practical buying gatekeeper: adoption requires changing graft handling, prophylaxis, scheduling, and monitoring rather than merely adding a drug. Post-transplant cyclophosphamide (PTCy) is a credible status-quo improvement: an EBMT review of a randomized 431-patient trial reported one-year chronic GVHD incidence of 21.9% with PTCy versus 35.1% with tacrolimus-methotrexate, and concluded that PTCy improved GVHD-free, relapse-free survival in the studied reduced-intensity setting. The evidence is not a head-to-head comparison with TREGZI, so it should be treated as a competing prophylaxis pathway, not proof of relative superiority.[CP001, CP002, CP003]

3.2 Product scope, clinical segment, and economics

Adjacent approved products demonstrate that the cell-therapy competitive set is segmented by indication and treatment moment. Ryoncil is an off-the-shelf mesenchymal stromal-cell therapy approved for steroid-refractory acute GVHD in pediatric patients, with a reported eight-infusion wholesale acquisition cost estimate of $1.55 million in the Summit Re article; it is not a direct substitute for TREGZI's adult matched-donor transplant use. Omisirge is a nicotinamide-modified cord-blood progenitor-cell therapy for patients receiving umbilical-cord transplantation or for severe aplastic anemia, with boxed warnings including GVHD, infusion reactions, graft failure, and engraftment syndrome. These products compete for transplant budgets, specialist attention, and institutional cell-therapy capability, but their labels and mechanisms differ materially. TREGZI's published wholesale acquisition cost is $428,000 according to the Life Science Daily article, which also describes a roughly 72-hour donor-to- infusion window and dedicated manufacturing. The figure is a list price, not realized net revenue, reimbursement, or contribution margin. Public sources in this pool do not establish discounting, payer coverage, center onboarding, or comparative total-cost-of-care outcomes.[CP004, CP005, CP006, CP007, CP008]

3.3 Differentiation durability and displacement risk

Orca Bio's strongest defensible differentiator is the combination of a precisely defined donor-derived graft and randomized evidence against the conventional allograft comparator. The company reports one-year chronic GVHD-free survival of 78% for TREGZI versus 38% for conventional alloHSCT (hazard ratio 0.26; p<0.00001), while the public trial record confirms the randomized, open-label, multicenter design and actual enrollment of 187 participants. A separate company-published retrospective analysis compared 76 TREGZI patients with 360 historical PTCy patients and reported three-year overall survival of 83% versus 66%; because the comparator is historical and the analysis is company-issued, it is directional rather than a clean competitive benchmark. The moat is therefore partly clinical and partly operational. A new entrant would need comparable evidence, donor-material logistics, validated manufacturing, and transplant-center workflow adoption. The same operating model creates displacement risk: the FDA review extension followed a major amendment involving chemistry, manufacturing, and controls information, and the label warns that graft failure, GVHD, infusion reactions, secondary malignancies, and transmission of infectious agents can occur. PTCy and conventional prophylaxis remain credible alternatives where centers value simpler workflows, while Ryoncil and Omisirge show that adjacent cell products can win narrower labels without matching TREGZI's mechanism.[CP009, CP010, CP011, CP012, CP013]

3.4 Exhibits

4.1 Revenue model and launch monetization

Tregzi is Orca Bio's first commercial product and creates a one-time, patient-specific product-sale opportunity rather than a recurring subscription stream. Independent reports consistently quote a $428,000 wholesale or wholesaler acquisition cost. Reuters reported that the company expected availability for orders by the end of July 2026, and Adam Feuerstein reported that commercial launch was underway. Neither statement establishes administered doses, recognized revenue, net price, paid claims, or cash collections. The public stream is therefore best modeled as one-time Tregzi product sales through qualified transplant centers, with partnership or licensing revenue left at zero until an executed agreement is produced. Pipeline programs are option value, not current revenue.[CI001, CI002, CI003, CI016]

4.2 Pricing, reimbursement, and GTM efficiency

The launch motion is provider-led and operationally gated. Public reports describe an initial limited-center rollout and a plan to expand to about 25 U.S. transplant centers by the end of 2026, but a center target is not evidence of activation, referrals, utilization, or sales efficiency. A reposted Orca Bio role for a Head of Business Development, reporting into the CFO or Head of Strategy, also points to active partnership and licensing work; it does not establish a commercial pipeline. Company statements that reimbursement pathways are in place likewise do not show authorization rates, negotiated reimbursement, denials, payment timing, or hospital economics. CAC, sales cycle, gross-to-net, and payback remain unavailable.[CI004, CI007, CI013, CI015]

4.3 Cost structure and manufacturing intensity

Tregzi's economics depend on a fresh, patient-specific supply chain. Reports describe matched-donor cells, separate cell components, and an approximately 72-hour interval from blood collection to infusion because the Tregs are not frozen. This creates labor, quality-control, logistics, facility-utilization, and failed-batch exposures that a wholesale price alone cannot resolve. The FDA's three-month review extension after an updated chemistry, manufacturing, and controls submission confirms that manufacturing evidence was material to regulatory review, although no additional clinical data were requested and approval followed. Public sources do not disclose fully loaded COGS, batch yield, failure cost, working capital, capex, or dose-level contribution margin.[CI005, CI006, CI011, CI016]

4.4 Capital adequacy and underwriting verdict

A company-issued financing announcement describes $250 million of new equity from Orca Bio's two most recent financing rounds plus up to $100 million of additional liquidity from a 2025 Silicon Valley Bank credit-facility amendment. These are financing measures, not current cash, undrawn availability, or runway. Multiples separately reports $442 million raised across two rounds, a third-party aggregation that should not be substituted for management's cash ledger. Clinical results provide a credible value proposition, but they do not establish commercial demand or margin. Until Orca Bio supplies current cash, burn, debt terms, launch volumes, net price, and dose-level COGS, the financial verdict is a potentially high-value launch with material capital, reimbursement, and execution uncertainty.[CI008, CI009, CI010, CI012, CI014]

4.5 Exhibits

5.1 Product definition and maturity

TREGZI is not a conventional drug or an off-the-shelf cell product. It is a personalized graft manufactured from an HLA-matched donor for adults with hematological malignancies undergoing matched-donor transplantation after myeloablative conditioning. The product separates the graft into hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, each assigned a distinct role in reconstitution, immune tolerance, and graft-versus- leukemia activity. FDA approval on June 30, 2026 materially de-risks clinical and regulatory maturity for the lead asset, but it does not establish commercial-scale manufacturing reliability. TREGZI is Orca Bio's first approved therapy; Orca-Q remains a reported pipeline asset whose current trial stage is not established by the assigned evidence. The product matrix therefore separates approved status, enabling technology, cellular components, and pipeline maturity rather than treating the platform as one uniformly validated asset.[CE001, CE002, CE004, CE007, CE012, CE013, CE016]

5.2 Architecture and operating workflow

The operating architecture couples donor qualification, precision cell separation, individualized dosing, time-sensitive logistics, and staged clinical administration. Public descriptions place hematopoietic stem and progenitor cells and regulatory T cells on day 0, followed by conventional T cells on day +2 or +3. A July 2026 independent article reported an approximately 72-hour blood-draw-to-infusion process, Sacramento manufacturing, and non-frozen regulatory T cells; these details are useful operating hypotheses, not audited service-level evidence. The workflow shifts risk from broad graft composition toward Orca Bio's ability to reproducibly purify, release, transport, and coordinate three cellular components within a specialist transplant setting. The public record does not disclose yield, batch-failure rate, release-test turnaround, shipping excursions, chain-of-identity exceptions, or center-level implementation time.[CE002, CE003, CE004, CE010, CE011]

5.3 Evidence-backed differentiation

The strongest differentiation is clinical rather than merely architectural. In the 187-patient randomized Precision-T study, company-reported approval materials state that 12-month chronic GVHD-free survival was 78% with TREGZI plus tacrolimus versus 38% with conventional allogeneic transplantation plus tacrolimus and methotrexate. The same source reported non-relapse mortality of 3% versus 13% and grade 3 or worse infections of 44% versus 51%. These results support the proposition that defined cellular composition can improve the transplant risk-benefit balance, but they should not be generalized beyond the approved matched-donor, myeloablative setting. A separate three-year overall-survival comparison was retrospective and used a registry cohort, so its reported 83% versus 66% result is supportive rather than equivalent to randomized evidence. Real-world effectiveness, center learning effects, and durability after launch remain unproven in the assigned public evidence.[CE005, CE006, CE007, CE014]

5.4 Controls, dependencies, and technical risks

Approval leaves substantial product and process risk. Prescribing-information language reproduced in the company releases identifies graft failure, acute and chronic GVHD, infusion reactions, secondary or donor-origin malignancies, and transmission of infectious agents as risks requiring screening and monitoring. Manufacturing controls also received direct regulatory scrutiny: Orca Bio said an updated chemistry, manufacturing, and controls submission was classified as a major BLA amendment and extended review by three months, although no additional clinical data were requested. That episode does not prove a quality defect, but it makes current CMC readiness, comparability, and release discipline priority diligence items. A company-issued recruiting post shows active interest in licensing and partnerships to expand the pipeline; it is a roadmap signal, not independent technical validation. No public developer or practitioner evidence in the assigned pool substantiates internal platform reproducibility, quality-system performance, cybersecurity, privacy, or chain-of-identity controls.[CE008, CE009, CE015]

5.5 Exhibits

6.1 Customer segments and purchase workflow

TREGZI is not sold into a broad, low-touch oncology market. Its initial operating customer is a transplant center capable of matched-donor allogeneic hematopoietic stem-cell transplantation, while transplant physicians select and treat patients, hospital teams coordinate the episode, and payers fund covered care. The labeled use is for adults with hematologic malignancies receiving a matched-donor transplant after myeloablative preparation. Because the product is manufactured for one patient from one matched donor, adoption requires clinical eligibility, donor collection, center scheduling, a manufacturing slot, infusion coordination, safety monitoring, benefit screening, authorization, coding, and billing. HRSA's nationwide transplant center inventory shows a geographically distributed addressable channel, but it does not identify which centers have contracted for, ordered, or infused TREGZI.[CU001, CU002, CU003, CU016]

6.2 Adoption proof and commercial trajectory

The strongest adoption-adjacent evidence is clinical rather than commercial. Orca's approval release reports that the randomized Precision-T study enrolled 187 patients across 19 U.S. treatment centers, and an earlier sponsor-submitted registry record reports 155 actual participants across a multi-state site network. Those records demonstrate that specialized centers could execute Orca-T protocols, but trial participation is not a paid production deployment. One independent launch account expected first orders within weeks of the June 2026 approval and roughly 25 U.S. transplant centers by year-end 2026. Both are forecasts, not observed order or active-account counts. The retained evidence provides no current denominator for completed commercial infusions, repeat orders, center conversion, utilization, or account-level revenue.[CU005, CU006, CU007, CU013, CU015]

6.3 Clinical value is established before commercial durability

Clinical outcomes give physicians a substantive reason to evaluate TREGZI. The approval evidence reports one-year overall survival of 94% versus 83% with conventional transplantation and GVHD-free, relapse-free survival of 63% versus 31%. Separately, Orca's retrospective phase 1b comparison reports one-, two-, and three-year overall survival of 96%, 86%, and 83% among 76 TREGZI recipients versus a 360-patient historical PTCy cohort. The retrospective design and historical control limit causal interpretation, and neither clinical data set measures customer renewal. Because TREGZI is an individualized one-time therapy, commercial durability should be assessed through repeat eligible-patient orders, additional active centers, payer approvals, manufacturing reliability, and contribution by account rather than subscription-style retention alone.[CU008, CU009, CU011, CU012, CU013]

6.4 Expansion and concentration risk

Publicly named institutions supply clinical-reference evidence, not verified customer evidence. Memorial Sloan Kettering and Stanford experts appear in approval coverage, and UCLA appears in the long-term clinical narrative and registry site list, but none of those references discloses a commercial contract, a paid infusion, or repeat use. Expansion therefore depends on converting a finite specialist-center channel and sustaining patient-specific manufacturing and payer authorization. A three-month BLA review extension followed updated chemistry, manufacturing, and controls information; approval ultimately occurred, but the episode is a relevant adverse signal for launch diligence. Without center-level orders, payer outcomes, capacity utilization, and revenue concentration, investors cannot distinguish broad uptake from dependence on a few trial-familiar centers.[CU010, CU013, CU014, CU015, CU016]

6.5 Exhibits

7.1 Regulatory and patient-safety exposure

FDA approval is a major de-risking event, but it is not a clean safety or compliance endpoint. TREGZI is approved only for matched-donor transplantation with myeloablative preparation in adults with hematological malignancies, and the published safety language identifies graft failure, life-threatening or fatal acute and chronic GVHD, serious infusion reactions, secondary or donor-origin malignancies, and transmission of infectious agents. These are clinically consequential hazards embedded in the product category rather than isolated historical incidents. The earlier three-month review extension after a major CMC amendment is resolved by approval, yet it demonstrates that manufacturing documentation can affect regulatory timing. Broader FDA flexibility for cell and gene therapy CMC requirements may reduce some process burden, but it does not remove product-specific release, comparability, pharmacovigilance, or change-control obligations. No exhaustive regulator, court, or enforcement search is available in the assigned evidence, so the absence of another recorded event must not be read as proof that none exists.[CR001, CR002, CR003, CR004, CR005, CR006, CR007, CR013]

7.2 Manufacturing, quality, and security control

TREGZI is not a conventional inventory product: it is manufactured for an individual patient from a matched donor and delivered as defined cellular components. Independent reporting says the unfrozen Treg component creates an approximately 72-hour blood-draw-to-infusion window, concentrating risk in donor coordination, collection, sorting, release testing, transport, and treatment-center scheduling. A third-party analysis reports Orca's low-single-digit failure rate across more than 500 clinical products, a useful historical benchmark but not yet evidence of commercial-scale performance. FACT standards show that cellular therapy quality spans collection, processing, and administration, so diligence cannot stop at Orca's plant. Digital operations add another layer: KPMG identifies availability, integrity, confidentiality, identity, and third-party risks across life sciences. The assigned evidence does not establish Orca's own cyber architecture, recovery objectives, validation controls, or incident history; those remain diligence items rather than inferred strengths.[CR008, CR009, CR010, CR015, CR016]

7.3 Commercialization and dependency risks

The initial commercial model depends on a narrow, specialized network rather than broad prescribing. Independent reporting describes a target of roughly 25 U.S. transplant centers by the end of 2026 and a reported wholesale acquisition cost of $428,000. Both metrics are planning signals, not realized adoption or net revenue. Each activated center must coordinate a matched donor, apheresis, a personalized three-component product, conditioning, infusion, monitoring, and payer authorization. The most important dependency is therefore the full donor-manufacturer-center-payer chain: failure at any link can delay treatment even when demand exists. The labeled indication also constrains the initial population to adults receiving matched-donor, myeloablative transplants. Payer policy, discounting, time to first commercial order, center throughput, and net collections are not established by the assigned sources. Funding raised or financing announcements would not answer the separate questions of cash on hand, burn, runway, or the capital required to support a national launch.[CR001, CR008, CR009, CR011, CR012]

7.4 Mitigations, monitors, and thesis-break triggers

The appropriate underwriting posture is milestone-based. Patient-safety mitigation should be tested through postmarketing event rates, engraftment monitoring, donor screening, infusion readiness, and long-horizon malignancy surveillance. Manufacturing mitigation should be measured through lot disposition, on-time delivery, chain-of-identity deviations, center-level cancellations, and performance by facility and lane; the reported low-single-digit clinical failure rate is the starting benchmark, not a guaranteed commercial ceiling. Commercial mitigation should be tracked against active treating centers rather than signed sites, with payer coverage, prior-authorization cycle time, gross-to-net deductions, and patient starts disclosed separately. Analyst-defined thesis-break triggers include a sustained material deterioration from the reported clinical manufacturing record, failure to activate a meaningful share of the stated 25-center plan by year-end, restrictive coverage that prevents eligible patient starts, a serious emerging safety signal, or a CMC action that interrupts supply. Cash, runway, cyber controls, and concentration by facility, payer, and center require primary diligence before investment sizing.[CR002, CR003, CR004, CR005, CR006, CR007, CR009, CR010, CR011, CR012, CR015, CR016]

7.5 Exhibits

8.1 Investment case and anti-thesis

The positive case is evidence-backed clinical differentiation rather than a proven financial franchise. The FDA approval announcement reports that the randomized Precision-T study enrolled 187 patients and that 12-month chronic GVHD-free survival was 78% with TREGZI versus 38% with conventional alloHSCT; overall survival was 94% versus 83%. That outcome can support a premium product position if transplant centers, payers, and patients adopt the therapy. Independent coverage describes the product as a personalized, donor-derived therapy and reports a $428,000 wholesale acquisition cost, a planned network of about 25 U.S. transplant centers by year-end 2026, and a second manufacturing facility. These are launch inputs, not evidence of booked revenue, realized price, margin, or repeat demand. The anti-thesis is that Orca Bio has one approved product and a highly individualized, manufacturing-intensive delivery model. The approval source itself lists graft failure, GVHD, infusion reactions, secondary malignancies, and infectious-agent transmission among warnings and precautions. The assigned sources also do not disclose a current valuation, liquidation preferences, dilution, cash runway, monthly burn, reimbursement outcomes, or post-approval utilization. Without those inputs, a precise price-to-sales or risk-adjusted NPV cannot be calculated responsibly. The recommendation therefore remains track/research-more, with a higher-quality call contingent on cap-table and launch evidence.[CV001, CV002, CV003, CV004, CV005]

8.2 Scenarios and entry discipline

A scenario framework is more decision-useful than a point valuation because the public record is strong on clinical efficacy but thin on economics. The bull case assumes the pivotal result translates into rapid center onboarding, payer coverage, reliable vein-to-vein manufacturing, and expansion beyond the initial label; the assigned independent article reports the company expected approximately 25 centers and first orders within weeks, but those are expectations, not realized observations. The base case assumes approval is followed by a measured launch while manufacturing, reimbursement, and center workflow constrain volume. The bear case assumes slow adoption, safety or CMC friction, or capital needs before commercial cash generation. Comparable evidence provides context but not a direct multiple. CompaniesMarketCap reports Legend Biotech at a $3.67 billion market capitalization on October 22, 2026, while an ACS Chemical & Engineering News account describes Gilead's 2017 Kite acquisition at $11.9 billion and notes the complexity of manufacturing individualized cell therapies. These public-company and M&A observations establish a range of sector outcomes, not a valuation for a private single-product issuer. The entry discipline is consequently to require a verified current mark, financing terms, cash runway, gross-margin bridge, center-level orders, payer coverage, and safety follow-up before underwriting a target return.[CV006, CV007, CV008, CV009, CV010]

8.3 Diligence asks and thesis-break triggers

The central valuation uncertainty is not whether Orca Bio has a credible clinical asset; it is whether the approved asset can become a repeatable, adequately financed commercial business at the price implied by the next financing or secondary transaction. A current mark should be reconciled to primary-versus-secondary proceeds and preference seniority. Commercial diligence should separate list price from net realized revenue and test whether transplant centers can operationalize donor collection, manufacturing, shipping, and infusion within the reported roughly 72-hour window. Financial diligence should reconcile the reported $250 million recent financing reference and $542 million funding total on Simplify with signed financing documents, cash on hand, burn, debt, and runway; these third-party listings are not audited financial statements. Thesis-break triggers are measurable: a material safety signal, a manufacturing or FDA CMC issue, failure to establish the planned center footprint, payer denials that prevent adoption, or a financing at a materially lower mark. The product's label also requires monitoring for graft failure and other serious complications, so post-marketing safety and real-world outcomes are valuation inputs rather than narrative qualifiers. Until those checks are completed, the evidence supports clinical promise and a watchlist position, not a buy call.[CV011, CV012, CV013, CV014]

8.4 Exhibits